New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
New published data shows Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for prostate cancer.
New published data shows Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for prostate cancer.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.